Alnylam Pharmaceuticals, Inc. (ALNY) 10-Year Financial Performance & Capital Metrics

ALNY •

HealthcareBiotechnologyRNA and Genome Editing Developers

AboutAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $3.71B +65.2%
EBITDA $557M +563.5%
Net Income $314M +212.8%
EPS (Diluted) 2.33 +206.9%
Gross Margin 81.77% -4.5%
EBITDA Margin 15% +380.6%
Operating Margin 13.51% +271.7%
Net Margin 8.45% +168.3%
ROE 73.28% +117.7%
ROIC 19.07% +252.1%
Debt/Equity 3.76 -90.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 49.8%

✗Weaknesses

✗High debt to equity ratio of 3.8x
✗Trading more than 30% below 52-week high
✗Expensive at 56.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y56.89%

5Y49.77%

3Y52.98%

TTM65.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM212.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM204.15%

ROCE

10Y Avg-25.97%

5Y Avg-10.53%

3Y Avg-0.23%

Latest15.31%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	47.16M	89.91M	74.91M	219.75M	492.85M	844.29M	1.04B	1.83B	2.25B	3.71B
Revenue Growth %	14.75%	90.66%	-16.69%	193.36%	124.28%	71.31%	22.88%	76.23%	22.97%	65.19%
Cost of Goods Sold+	0	13.37M	1.8M	25.06M	78.05M	140.14M	168.82M	310.41M	323.37M	677.17M
COGS % of Revenue	-	14.87%	2.41%	11.4%	15.84%	16.6%	16.27%	16.98%	14.38%	18.23%
Gross Profit+	47.16M	76.55M	73.11M	194.69M	414.8M	704.14M	868.6M	1.52B	1.92B	3.04B
Gross Margin %	100%	85.13%	97.59%	88.6%	84.16%	83.4%	83.73%	83.02%	85.62%	81.77%
Gross Profit Growth %	14.75%	62.31%	-4.49%	166.31%	113.06%	69.75%	23.36%	74.75%	26.81%	57.76%
Operating Expenses+	471.75M	590M	887.78M	1.13B	1.24B	1.41B	1.65B	1.8B	2.1B	2.54B
OpEx % of Revenue	1000.33%	656.2%	1185.16%	516.1%	252.25%	167.34%	159.4%	98.46%	93.48%	68.26%
Selling, General & Admin	89.35M	199.37M	382.36M	479M	588.42M	620.64M	770.66M	795.65M	975.53M	1.21B
SG&A % of Revenue	189.47%	221.73%	510.44%	217.98%	119.39%	73.51%	74.29%	43.52%	43.39%	32.6%
Research & Development	382.39M	390.63M	505.42M	655.11M	654.82M	792.16M	883.01M	1B	1.13B	1.32B
R&D % of Revenue	810.86%	434.46%	674.72%	298.12%	132.86%	93.83%	85.12%	54.94%	50.09%	35.66%
Other Operating Expenses	0	-3.02M	4.17M	0	0	-2.05M	0	0	0	0
Operating Income+	-424.59M	-500.09M	-814.67M	-939.43M	-828.44M	-708.65M	-785.07M	-282.18M	-176.88M	501.58M
Operating Margin %	-900.33%	-556.2%	-1087.56%	-427.5%	-168.09%	-83.94%	-75.68%	-15.43%	-7.87%	13.51%
Operating Income Growth %	-43.44%	-17.78%	-62.91%	-15.31%	11.81%	14.46%	-10.78%	64.06%	37.31%	383.56%
EBITDA+	-409.46M	-486.72M	-808.24M	-922.26M	-793.67M	-661.09M	-740.6M	-228.12M	-120.22M	557.24M
EBITDA Margin %	-868.25%	-541.33%	-1078.97%	-419.68%	-161.03%	-78.3%	-71.39%	-12.48%	-5.35%	15%
EBITDA Growth %	-47.84%	-18.87%	-66.06%	-14.11%	13.94%	16.7%	-12.03%	69.2%	47.3%	563.53%
D&A (Non-Cash Add-back)	15.13M	13.37M	6.43M	17.18M	34.77M	47.57M	44.47M	54.05M	56.67M	55.66M
EBIT	-424.59M	-500.09M	-760.67M	-885.25M	-771.1M	-709.12M	-971.02M	-312.3M	-235.52M	501.58M
Net Interest Income+	8.31M	12.24M	29.26M	33.45M	-72.69M	-141.44M	-131.16M	-25.66M	-19.87M	0
Interest Income	8.31M	12.24M	29.26M	33.45M	11.81M	1.58M	24.81M	95.56M	121.99M	0
Interest Expense	0	0	0	0	84.5M	143.02M	155.97M	121.22M	141.86M	0
Other Income/Expense	14.48M	9.21M	54M	54.18M	-27.16M	-143.49M	-341.92M	-151.34M	-200.49M	-178.43M
Pretax Income+	-410.11M	-490.87M	-760.67M	-885.25M	-855.6M	-852.14M	-1.13B	-433.52M	-377.38M	323.15M
Pretax Margin %	-869.63%	-545.95%	-1015.48%	-402.85%	-173.6%	-100.93%	-108.63%	-23.71%	-16.79%	8.7%
Income Tax+	0	0	823K	863K	2.68M	680K	4.16M	6.72M	-99.22M	9.4M
Effective Tax Rate %	100%	100%	100.11%	100.1%	100.31%	100.08%	100.37%	101.55%	73.71%	97.09%
Net Income+	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Net Margin %	-869.63%	-545.95%	-1016.58%	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-12.37%	8.45%
Net Income Growth %	-41.38%	-19.69%	-55.13%	-16.36%	3.14%	0.64%	-32.64%	61.08%	36.82%	212.79%
Net Income (Continuing)	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.79	-5.42	-7.57	-8.11	-7.46	-7.20	-9.30	-3.52	-2.18	2.33
EPS Growth %	-38.84%	-13.15%	-39.67%	-7.13%	8.01%	3.49%	-29.17%	62.15%	38.07%	206.88%
EPS (Basic)	-4.79	-5.42	-7.57	-8.11	-7.46	-7.20	-9.30	-3.52	-2.18	2.39
Diluted Shares Outstanding	85.6M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M	134.68M
Basic Shares Outstanding	85.6M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M	131M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	671.88M	1.76B	1.2B	1.72B	2.61B	2.81B	2.69B	2.98B	3.3B	4.05B
Cash & Short-Term Investments	626.8M	1.69B	1.08B	1.54B	1.87B	2.44B	2.19B	2.44B	2.69B	2.91B
Cash Only	193.62M	645.36M	420.15M	547.18M	496.58M	819.98M	866.39M	812.69M	966.43M	1.66B
Short-Term Investments	433.18M	1.05B	664.01M	988.98M	1.38B	1.62B	1.33B	1.63B	1.73B	1.25B
Accounts Receivable	23.33M	34M	18.76M	43.01M	602.41M	198.57M	237.96M	327.79M	405.31M	777.57M
Days Sales Outstanding	180.6	138.03	91.41	71.44	446.14	85.85	83.72	65.44	65.8	76.42
Inventory	0	0	24.07M	56.35M	75.2M	86.36M	128.96M	89.15M	78.51M	82.72M
Days Inventory Outstanding	-	-	4.88K	820.65	351.67	224.93	278.83	104.82	88.62	44.59
Other Current Assets	0	0	0	0	0	0	132.92M	126.38M	116.96M	0
Total Non-Current Assets+	590.93M	229.99M	374.11M	679.27M	792.28M	834.73M	854.11M	847.18M	944.7M	915.67M
Property, Plant & Equipment	114.57M	181.9M	320.66M	646.38M	706.51M	733.63M	738.63M	725.79M	693.93M	-59.18M
Fixed Asset Turnover	0.41x	0.49x	0.23x	0.34x	0.70x	1.15x	1.40x	2.52x	3.24x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	593.73M
Long-Term Investments	324.8M	13.92M	44.83M	14.82M	0	0	0	0	0	0
Other Non-Current Assets	151.56M	34.17M	8.62M	18.07M	85.77M	101.09M	115.48M	111.29M	133.9M	-2.54B
Total Assets+	1.26B	1.99B	1.57B	2.4B	3.41B	3.64B	3.55B	3.83B	4.24B	4.97B
Asset Turnover	0.04x	0.05x	0.05x	0.09x	0.14x	0.23x	0.29x	0.48x	0.53x	0.75x
Asset Growth %	-8.92%	57.96%	-21.05%	52.09%	42.25%	6.93%	-2.66%	7.99%	10.71%	17.13%
Total Current Liabilities+	131.7M	144.25M	179.49M	352.59M	585.27M	695.71M	767.91M	967.79M	1.19B	1.47B
Accounts Payable	54.47M	28.36M	59.71M	49.88M	51.97M	73.43M	98.09M	55.52M	88.42M	115.72M
Days Payables Outstanding	-	774.26	12.09K	726.5	243.01	191.24	212.09	65.28	99.8	62.37
Short-Term Debt	0	0	0	0	0	0	0	0	113.02M	220.07M
Deferred Revenue (Current)	33.54M	41.7M	3.5M	77.82M	127.21M	149.48M	42.1M	102.75M	55.48M	1.22M
Other Current Liabilities	15.27M	35.81M	40.87M	68.3M	110.75M	130.66M	170.98M	177.16M	214.4M	1.08B
Current Ratio	5.10x	12.23x	6.69x	4.87x	4.47x	4.04x	3.51x	3.08x	2.78x	2.76x
Quick Ratio	5.10x	12.23x	6.56x	4.71x	4.34x	3.91x	3.34x	2.99x	2.71x	2.71x
Cash Conversion Cycle	-	-	-7.13K	165.58	554.8	119.54	150.46	104.98	54.62	58.63
Total Non-Current Liabilities+	210.89M	84.05M	93.34M	603.85M	1.81B	2.36B	2.94B	3.08B	2.99B	2.71B
Long-Term Debt	150M	30M	30M	0	191.28M	675.7M	1.02B	1.02B	2.36B	2.48B
Capital Lease Obligations	0	0	0	276.13M	293.04M	281.35M	261.34M	243.1M	229.54M	225.09M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.5M	10.97M	62.88M	9.33M	1.1B	1.25B	1.46B	1.63B	398.11M	7.59M
Total Liabilities	342.59M	228.3M	272.84M	956.44M	2.39B	3.06B	3.7B	4.05B	4.17B	4.18B
Total Debt+	150M	30M	30M	303.82M	521.19M	997.59M	1.32B	1.31B	2.74B	2.97B
Net Debt	-43.62M	-615.36M	-390.15M	-243.35M	24.61M	177.62M	453.85M	492.7M	1.78B	1.31B
Debt / Equity	0.16x	0.02x	0.02x	0.21x	0.51x	1.70x	-	-	40.89x	3.76x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	5.33x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	2.35x
Interest Coverage	-	-	-	-	-9.80x	-4.95x	-5.03x	-2.33x	-1.25x	-
Total Equity+	920.22M	1.77B	1.3B	1.44B	1.02B	588.2M	-158.22M	-220.64M	67.09M	789.18M
Equity Growth %	-27.24%	91.96%	-26.29%	10.5%	-29.36%	-42.12%	-126.9%	-39.45%	130.41%	1076.33%
Book Value per Share	10.75	19.51	12.94	13.17	8.84	4.97	-1.30	-1.77	0.53	5.86
Total Shareholders' Equity	920.22M	1.77B	1.3B	1.44B	1.02B	588.2M	-158.22M	-220.64M	67.09M	789.18M
Common Stock	859K	997K	1.01M	1.12M	1.16M	1.2M	1.24M	1.26M	1.29M	1.32M
Retained Earnings	-1.66B	-2.15B	-2.84B	-3.73B	-4.59B	-5.44B	-6.57B	-7.01B	-7.29B	-6.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-33.44M	-34.43M	-33.21M	-36.52M	-43.62M	-33.26M	-44.65M	-23.38M	-34.52M	-20.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-307.7M	-382.79M	-562.62M	-278.43M	-614.96M	-641.69M	-541.27M	104.16M	-8.31M	524.08M
Operating CF Margin %	-652.48%	-425.73%	-751.08%	-126.7%	-124.78%	-76%	-52.18%	5.7%	-0.37%	14.11%
Operating CF Growth %	-62.68%	-24.4%	-46.98%	50.51%	-120.87%	-4.35%	15.65%	119.24%	-107.98%	6405.1%
Net Income	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Depreciation & Amortization	15.13M	13.37M	6.43M	54.37M	74.44M	89.69M	85.55M	97.03M	56.67M	55.66M
Stock-Based Compensation	75.53M	92.82M	157.75M	174.84M	139.87M	165.72M	230.65M	221.68M	272.08M	348.24M
Deferred Taxes	-6.98M	1.89M	-3.56M	-11.29M	-54.04M	-55.7M	0	0	-106.76M	-2.2M
Other Non-Cash Items	1.51M	2.91M	-6.84M	-12.61M	95.75M	174.24M	309.24M	214.93M	261.94M	277.85M
Working Capital Changes	17.22M	-2.9M	45.1M	402.38M	-12.7M	-162.82M	-35.55M	10.76M	-214.08M	-469.21M
Change in Receivables	-15.04M	-10.67M	15.24M	-24.24M	-56.24M	-101.8M	-45.6M	-87.94M	-86.55M	-359.96M
Change in Inventory	0	0	-22.64M	-32.41M	-35.43M	-26.41M	-34.14M	18.37M	13.59M	8.47M
Change in Payables	10.1M	-4.94M	15.48M	36.61M	117.38M	88.24M	191.77M	80.84M	91.09M	75.07M
Cash from Investing+	142.59M	-290.36M	272.94M	-417.68M	-435.52M	-273.3M	169.35M	-336.35M	-116.84M	436.33M
Capital Expenditures	-64.56M	-104.21M	-126.89M	-140.16M	-70.36M	-76.37M	-72.06M	-62.21M	-34.28M	-58.7M
CapEx % of Revenue	136.89%	115.9%	169.39%	63.78%	14.28%	9.05%	6.95%	3.4%	1.52%	1.58%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-150M	120M	-14.82M	23M	-31.2M	-4.36M	-13.19M	-4.44M	57.76M	57.63M
Cash from Financing+	177.83M	1.12B	65.47M	823.18M	994.98M	1.25B	425.75M	172.13M	294.16M	-305.19M
Debt Issued (Net)	150M	-120M	0	-30M	200M	500M	254M	0	0	-546.95M
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-596K	-257K	-3.47M	0	0	0	0	0	0	0
Other Financing	14.13M	83.89M	0	71.28M	695.48M	500.85M	-87.61M	24.67M	-8.79M	241.76M
Net Change in Cash	12.72M	451.74M	-224.2M	127M	-50.58M	323.11M	46.4M	-53.67M	153.77M	690.15M
Free Cash Flow+	-372.26M	-487M	-689.5M	-418.58M	-685.32M	-718.07M	-613.33M	41.95M	-42.59M	465.38M
FCF Margin %	-789.37%	-541.64%	-920.47%	-190.48%	-139.05%	-85.05%	-59.12%	2.29%	-1.89%	12.53%
FCF Growth %	-84.2%	-30.82%	-41.58%	39.29%	-63.72%	-4.78%	14.59%	106.84%	-201.54%	1192.73%
FCF per Share	-4.35	-5.38	-6.85	-3.83	-5.96	-6.06	-5.04	0.34	-0.33	3.46
FCF Conversion (FCF/Net Income)	0.75x	0.78x	0.74x	0.31x	0.72x	0.75x	0.48x	-0.24x	0.03x	1.67x
Interest Paid	1.1M	2.43M	775K	172K	0	0	0	0	67.58M	0
Taxes Paid	111K	114K	1.07M	2.57M	0	0	0	0	14.36M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-37.54%	-36.54%	-49.63%	-64.66%	-69.92%	-106.31%	-526.14%	-	-414.62%	73.28%
Return on Invested Capital (ROIC)	-32.49%	-36.99%	-59.24%	-66.87%	-55.57%	-58.84%	-110.94%	-74.56%	-12.54%	19.07%
Gross Margin	100%	85.13%	97.59%	88.6%	84.16%	83.4%	83.73%	83.02%	85.62%	81.77%
Net Margin	-869.63%	-545.95%	-1016.58%	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-12.37%	8.45%
Debt / Equity	0.16x	0.02x	0.02x	0.21x	0.51x	1.70x	-	-	40.89x	3.76x
Interest Coverage	-	-	-	-	-9.80x	-4.95x	-5.03x	-2.33x	-1.25x	-
FCF Conversion	0.75x	0.78x	0.74x	0.31x	0.72x	0.75x	0.48x	-0.24x	0.03x	1.67x
Revenue Growth	14.75%	90.66%	-16.69%	193.36%	124.28%	71.31%	22.88%	76.23%	22.97%	65.19%

US Stock Screener

...

Alnylam Pharmaceuticals, Inc. (ALNY) 10-Year Financial Performance & Capital Metrics

ALNY •

HealthcareBiotechnologyRNA and Genome Editing Developers

Revenue $3.71B +65.2%
EBITDA $557M +563.5%
Net Income $314M +212.8%
EPS (Diluted) 2.33 +206.9%
Gross Margin 81.77% -4.5%
EBITDA Margin 15% +380.6%
Operating Margin 13.51% +271.7%
Net Margin 8.45% +168.3%
ROE 73.28% +117.7%
ROIC 19.07% +252.1%
Debt/Equity 3.76 -90.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 49.8%

✗Weaknesses

✗High debt to equity ratio of 3.8x
✗Trading more than 30% below 52-week high
✗Expensive at 56.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y56.89%

5Y49.77%

3Y52.98%

TTM65.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM212.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM204.15%

ROCE

10Y Avg-25.97%

5Y Avg-10.53%

3Y Avg-0.23%

Latest15.31%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	47.16M	89.91M	74.91M	219.75M	492.85M	844.29M	1.04B	1.83B	2.25B	3.71B
Revenue Growth %	14.75%	90.66%	-16.69%	193.36%	124.28%	71.31%	22.88%	76.23%	22.97%	65.19%
Cost of Goods Sold+	0	13.37M	1.8M	25.06M	78.05M	140.14M	168.82M	310.41M	323.37M	677.17M
COGS % of Revenue	-	14.87%	2.41%	11.4%	15.84%	16.6%	16.27%	16.98%	14.38%	18.23%
Gross Profit+	47.16M	76.55M	73.11M	194.69M	414.8M	704.14M	868.6M	1.52B	1.92B	3.04B
Gross Margin %	100%	85.13%	97.59%	88.6%	84.16%	83.4%	83.73%	83.02%	85.62%	81.77%
Gross Profit Growth %	14.75%	62.31%	-4.49%	166.31%	113.06%	69.75%	23.36%	74.75%	26.81%	57.76%
Operating Expenses+	471.75M	590M	887.78M	1.13B	1.24B	1.41B	1.65B	1.8B	2.1B	2.54B
OpEx % of Revenue	1000.33%	656.2%	1185.16%	516.1%	252.25%	167.34%	159.4%	98.46%	93.48%	68.26%
Selling, General & Admin	89.35M	199.37M	382.36M	479M	588.42M	620.64M	770.66M	795.65M	975.53M	1.21B
SG&A % of Revenue	189.47%	221.73%	510.44%	217.98%	119.39%	73.51%	74.29%	43.52%	43.39%	32.6%
Research & Development	382.39M	390.63M	505.42M	655.11M	654.82M	792.16M	883.01M	1B	1.13B	1.32B
R&D % of Revenue	810.86%	434.46%	674.72%	298.12%	132.86%	93.83%	85.12%	54.94%	50.09%	35.66%
Other Operating Expenses	0	-3.02M	4.17M	0	0	-2.05M	0	0	0	0
Operating Income+	-424.59M	-500.09M	-814.67M	-939.43M	-828.44M	-708.65M	-785.07M	-282.18M	-176.88M	501.58M
Operating Margin %	-900.33%	-556.2%	-1087.56%	-427.5%	-168.09%	-83.94%	-75.68%	-15.43%	-7.87%	13.51%
Operating Income Growth %	-43.44%	-17.78%	-62.91%	-15.31%	11.81%	14.46%	-10.78%	64.06%	37.31%	383.56%
EBITDA+	-409.46M	-486.72M	-808.24M	-922.26M	-793.67M	-661.09M	-740.6M	-228.12M	-120.22M	557.24M
EBITDA Margin %	-868.25%	-541.33%	-1078.97%	-419.68%	-161.03%	-78.3%	-71.39%	-12.48%	-5.35%	15%
EBITDA Growth %	-47.84%	-18.87%	-66.06%	-14.11%	13.94%	16.7%	-12.03%	69.2%	47.3%	563.53%
D&A (Non-Cash Add-back)	15.13M	13.37M	6.43M	17.18M	34.77M	47.57M	44.47M	54.05M	56.67M	55.66M
EBIT	-424.59M	-500.09M	-760.67M	-885.25M	-771.1M	-709.12M	-971.02M	-312.3M	-235.52M	501.58M
Net Interest Income+	8.31M	12.24M	29.26M	33.45M	-72.69M	-141.44M	-131.16M	-25.66M	-19.87M	0
Interest Income	8.31M	12.24M	29.26M	33.45M	11.81M	1.58M	24.81M	95.56M	121.99M	0
Interest Expense	0	0	0	0	84.5M	143.02M	155.97M	121.22M	141.86M	0
Other Income/Expense	14.48M	9.21M	54M	54.18M	-27.16M	-143.49M	-341.92M	-151.34M	-200.49M	-178.43M
Pretax Income+	-410.11M	-490.87M	-760.67M	-885.25M	-855.6M	-852.14M	-1.13B	-433.52M	-377.38M	323.15M
Pretax Margin %	-869.63%	-545.95%	-1015.48%	-402.85%	-173.6%	-100.93%	-108.63%	-23.71%	-16.79%	8.7%
Income Tax+	0	0	823K	863K	2.68M	680K	4.16M	6.72M	-99.22M	9.4M
Effective Tax Rate %	100%	100%	100.11%	100.1%	100.31%	100.08%	100.37%	101.55%	73.71%	97.09%
Net Income+	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Net Margin %	-869.63%	-545.95%	-1016.58%	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-12.37%	8.45%
Net Income Growth %	-41.38%	-19.69%	-55.13%	-16.36%	3.14%	0.64%	-32.64%	61.08%	36.82%	212.79%
Net Income (Continuing)	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.79	-5.42	-7.57	-8.11	-7.46	-7.20	-9.30	-3.52	-2.18	2.33
EPS Growth %	-38.84%	-13.15%	-39.67%	-7.13%	8.01%	3.49%	-29.17%	62.15%	38.07%	206.88%
EPS (Basic)	-4.79	-5.42	-7.57	-8.11	-7.46	-7.20	-9.30	-3.52	-2.18	2.39
Diluted Shares Outstanding	85.6M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M	134.68M
Basic Shares Outstanding	85.6M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M	131M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	671.88M	1.76B	1.2B	1.72B	2.61B	2.81B	2.69B	2.98B	3.3B	4.05B
Cash & Short-Term Investments	626.8M	1.69B	1.08B	1.54B	1.87B	2.44B	2.19B	2.44B	2.69B	2.91B
Cash Only	193.62M	645.36M	420.15M	547.18M	496.58M	819.98M	866.39M	812.69M	966.43M	1.66B
Short-Term Investments	433.18M	1.05B	664.01M	988.98M	1.38B	1.62B	1.33B	1.63B	1.73B	1.25B
Accounts Receivable	23.33M	34M	18.76M	43.01M	602.41M	198.57M	237.96M	327.79M	405.31M	777.57M
Days Sales Outstanding	180.6	138.03	91.41	71.44	446.14	85.85	83.72	65.44	65.8	76.42
Inventory	0	0	24.07M	56.35M	75.2M	86.36M	128.96M	89.15M	78.51M	82.72M
Days Inventory Outstanding	-	-	4.88K	820.65	351.67	224.93	278.83	104.82	88.62	44.59
Other Current Assets	0	0	0	0	0	0	132.92M	126.38M	116.96M	0
Total Non-Current Assets+	590.93M	229.99M	374.11M	679.27M	792.28M	834.73M	854.11M	847.18M	944.7M	915.67M
Property, Plant & Equipment	114.57M	181.9M	320.66M	646.38M	706.51M	733.63M	738.63M	725.79M	693.93M	-59.18M
Fixed Asset Turnover	0.41x	0.49x	0.23x	0.34x	0.70x	1.15x	1.40x	2.52x	3.24x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	593.73M
Long-Term Investments	324.8M	13.92M	44.83M	14.82M	0	0	0	0	0	0
Other Non-Current Assets	151.56M	34.17M	8.62M	18.07M	85.77M	101.09M	115.48M	111.29M	133.9M	-2.54B
Total Assets+	1.26B	1.99B	1.57B	2.4B	3.41B	3.64B	3.55B	3.83B	4.24B	4.97B
Asset Turnover	0.04x	0.05x	0.05x	0.09x	0.14x	0.23x	0.29x	0.48x	0.53x	0.75x
Asset Growth %	-8.92%	57.96%	-21.05%	52.09%	42.25%	6.93%	-2.66%	7.99%	10.71%	17.13%
Total Current Liabilities+	131.7M	144.25M	179.49M	352.59M	585.27M	695.71M	767.91M	967.79M	1.19B	1.47B
Accounts Payable	54.47M	28.36M	59.71M	49.88M	51.97M	73.43M	98.09M	55.52M	88.42M	115.72M
Days Payables Outstanding	-	774.26	12.09K	726.5	243.01	191.24	212.09	65.28	99.8	62.37
Short-Term Debt	0	0	0	0	0	0	0	0	113.02M	220.07M
Deferred Revenue (Current)	33.54M	41.7M	3.5M	77.82M	127.21M	149.48M	42.1M	102.75M	55.48M	1.22M
Other Current Liabilities	15.27M	35.81M	40.87M	68.3M	110.75M	130.66M	170.98M	177.16M	214.4M	1.08B
Current Ratio	5.10x	12.23x	6.69x	4.87x	4.47x	4.04x	3.51x	3.08x	2.78x	2.76x
Quick Ratio	5.10x	12.23x	6.56x	4.71x	4.34x	3.91x	3.34x	2.99x	2.71x	2.71x
Cash Conversion Cycle	-	-	-7.13K	165.58	554.8	119.54	150.46	104.98	54.62	58.63
Total Non-Current Liabilities+	210.89M	84.05M	93.34M	603.85M	1.81B	2.36B	2.94B	3.08B	2.99B	2.71B
Long-Term Debt	150M	30M	30M	0	191.28M	675.7M	1.02B	1.02B	2.36B	2.48B
Capital Lease Obligations	0	0	0	276.13M	293.04M	281.35M	261.34M	243.1M	229.54M	225.09M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.5M	10.97M	62.88M	9.33M	1.1B	1.25B	1.46B	1.63B	398.11M	7.59M
Total Liabilities	342.59M	228.3M	272.84M	956.44M	2.39B	3.06B	3.7B	4.05B	4.17B	4.18B
Total Debt+	150M	30M	30M	303.82M	521.19M	997.59M	1.32B	1.31B	2.74B	2.97B
Net Debt	-43.62M	-615.36M	-390.15M	-243.35M	24.61M	177.62M	453.85M	492.7M	1.78B	1.31B
Debt / Equity	0.16x	0.02x	0.02x	0.21x	0.51x	1.70x	-	-	40.89x	3.76x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	5.33x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	2.35x
Interest Coverage	-	-	-	-	-9.80x	-4.95x	-5.03x	-2.33x	-1.25x	-
Total Equity+	920.22M	1.77B	1.3B	1.44B	1.02B	588.2M	-158.22M	-220.64M	67.09M	789.18M
Equity Growth %	-27.24%	91.96%	-26.29%	10.5%	-29.36%	-42.12%	-126.9%	-39.45%	130.41%	1076.33%
Book Value per Share	10.75	19.51	12.94	13.17	8.84	4.97	-1.30	-1.77	0.53	5.86
Total Shareholders' Equity	920.22M	1.77B	1.3B	1.44B	1.02B	588.2M	-158.22M	-220.64M	67.09M	789.18M
Common Stock	859K	997K	1.01M	1.12M	1.16M	1.2M	1.24M	1.26M	1.29M	1.32M
Retained Earnings	-1.66B	-2.15B	-2.84B	-3.73B	-4.59B	-5.44B	-6.57B	-7.01B	-7.29B	-6.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-33.44M	-34.43M	-33.21M	-36.52M	-43.62M	-33.26M	-44.65M	-23.38M	-34.52M	-20.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-307.7M	-382.79M	-562.62M	-278.43M	-614.96M	-641.69M	-541.27M	104.16M	-8.31M	524.08M
Operating CF Margin %	-652.48%	-425.73%	-751.08%	-126.7%	-124.78%	-76%	-52.18%	5.7%	-0.37%	14.11%
Operating CF Growth %	-62.68%	-24.4%	-46.98%	50.51%	-120.87%	-4.35%	15.65%	119.24%	-107.98%	6405.1%
Net Income	-410.11M	-490.87M	-761.5M	-886.12M	-858.28M	-852.82M	-1.13B	-440.24M	-278.16M	313.75M
Depreciation & Amortization	15.13M	13.37M	6.43M	54.37M	74.44M	89.69M	85.55M	97.03M	56.67M	55.66M
Stock-Based Compensation	75.53M	92.82M	157.75M	174.84M	139.87M	165.72M	230.65M	221.68M	272.08M	348.24M
Deferred Taxes	-6.98M	1.89M	-3.56M	-11.29M	-54.04M	-55.7M	0	0	-106.76M	-2.2M
Other Non-Cash Items	1.51M	2.91M	-6.84M	-12.61M	95.75M	174.24M	309.24M	214.93M	261.94M	277.85M
Working Capital Changes	17.22M	-2.9M	45.1M	402.38M	-12.7M	-162.82M	-35.55M	10.76M	-214.08M	-469.21M
Change in Receivables	-15.04M	-10.67M	15.24M	-24.24M	-56.24M	-101.8M	-45.6M	-87.94M	-86.55M	-359.96M
Change in Inventory	0	0	-22.64M	-32.41M	-35.43M	-26.41M	-34.14M	18.37M	13.59M	8.47M
Change in Payables	10.1M	-4.94M	15.48M	36.61M	117.38M	88.24M	191.77M	80.84M	91.09M	75.07M
Cash from Investing+	142.59M	-290.36M	272.94M	-417.68M	-435.52M	-273.3M	169.35M	-336.35M	-116.84M	436.33M
Capital Expenditures	-64.56M	-104.21M	-126.89M	-140.16M	-70.36M	-76.37M	-72.06M	-62.21M	-34.28M	-58.7M
CapEx % of Revenue	136.89%	115.9%	169.39%	63.78%	14.28%	9.05%	6.95%	3.4%	1.52%	1.58%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-150M	120M	-14.82M	23M	-31.2M	-4.36M	-13.19M	-4.44M	57.76M	57.63M
Cash from Financing+	177.83M	1.12B	65.47M	823.18M	994.98M	1.25B	425.75M	172.13M	294.16M	-305.19M
Debt Issued (Net)	150M	-120M	0	-30M	200M	500M	254M	0	0	-546.95M
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-596K	-257K	-3.47M	0	0	0	0	0	0	0
Other Financing	14.13M	83.89M	0	71.28M	695.48M	500.85M	-87.61M	24.67M	-8.79M	241.76M
Net Change in Cash	12.72M	451.74M	-224.2M	127M	-50.58M	323.11M	46.4M	-53.67M	153.77M	690.15M
Free Cash Flow+	-372.26M	-487M	-689.5M	-418.58M	-685.32M	-718.07M	-613.33M	41.95M	-42.59M	465.38M
FCF Margin %	-789.37%	-541.64%	-920.47%	-190.48%	-139.05%	-85.05%	-59.12%	2.29%	-1.89%	12.53%
FCF Growth %	-84.2%	-30.82%	-41.58%	39.29%	-63.72%	-4.78%	14.59%	106.84%	-201.54%	1192.73%
FCF per Share	-4.35	-5.38	-6.85	-3.83	-5.96	-6.06	-5.04	0.34	-0.33	3.46
FCF Conversion (FCF/Net Income)	0.75x	0.78x	0.74x	0.31x	0.72x	0.75x	0.48x	-0.24x	0.03x	1.67x
Interest Paid	1.1M	2.43M	775K	172K	0	0	0	0	67.58M	0
Taxes Paid	111K	114K	1.07M	2.57M	0	0	0	0	14.36M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-37.54%	-36.54%	-49.63%	-64.66%	-69.92%	-106.31%	-526.14%	-	-414.62%	73.28%
Return on Invested Capital (ROIC)	-32.49%	-36.99%	-59.24%	-66.87%	-55.57%	-58.84%	-110.94%	-74.56%	-12.54%	19.07%
Gross Margin	100%	85.13%	97.59%	88.6%	84.16%	83.4%	83.73%	83.02%	85.62%	81.77%
Net Margin	-869.63%	-545.95%	-1016.58%	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-12.37%	8.45%
Debt / Equity	0.16x	0.02x	0.02x	0.21x	0.51x	1.70x	-	-	40.89x	3.76x
Interest Coverage	-	-	-	-	-9.80x	-4.95x	-5.03x	-2.33x	-1.25x	-
FCF Conversion	0.75x	0.78x	0.74x	0.31x	0.72x	0.75x	0.48x	-0.24x	0.03x	1.67x
Revenue Growth	14.75%	90.66%	-16.69%	193.36%	124.28%	71.31%	22.88%	76.23%	22.97%	65.19%

Alnylam Pharmaceuticals, Inc. (ALNY) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ALNY vs Peers

vs IONS

vs ARWR

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Alnylam Pharmaceuticals, Inc. (ALNY) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ALNY vs Peers

vs IONS

vs ARWR

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios